Current price is less than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Marksans Pharma Looks Attractive

Aarti Industries, Abbott India, Agarwal Industrial Corporation, AIA Engineering, GE Power, Apollo Tyres, Balkrishna Industries, Bharat Forge, CESC, Dish TV, Eros International, FDC, Future Lifestyle, GMR Airports, Grasim Industries, Hinduja Global, JM Financial, Khaitan, Kaveri Seed, Marksans Pharma…

Q2 results this week: Aarti Industries, Abbott India and more

Suzlon Energy and Marksans Pharma stock in the news this afternoon. Listen in.

#suzlonenergy #suzlonenergystock #marksanspharma #stockmarketupdates #cnbctv18 
#businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday 

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. #n18oc_business  Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action: https://www.cnbctv18.com/market/

Follow experts on the most vital topics: https://www.cnbctv18.com/expert-views/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

n18oc_business

Suzlon Energy And Marksans Pharma Stocks Buzzing In Trade | Business Lunch | CNBC-TV18

Through the acquisition, the company plans to double its existing Indian capacity from 8 billion units per annum currently

Capacity addition from Tevapharm sends Marksans Pharma up 6%

Marksans Pharma jumped 8.15% to Rs 50.45 after the drug firm said it has inked a pact with Tevapharm India to acquire its Goa-based pharmaceutical formulations business.

Marksans Pharma spurts on buying Tevapharm’s bulk formulations biz

Buzzing stocks: Infosys, HCL Tech, Wipro, Suzlon, SW Solar, Cipla, Marksans Pharma, Brigade Enterprises, L&T Finance Holdings, Genesys International, Kirloskar Electric, Fino Payments, IndusInd Bank, Inox Leisure

Stocks that will see action on October 12

The company via its regulatory filing has informed the exchanges that it has entered into a business agreement to acquire Tevapharm India’s Goa-based bulk pharmaceutical formulations business.

Marksans Pharma rallies ~12% as company to acquire Tevapharm’s Goa facility

The manufacturing site is spread across 47,597 sq meters and has approvals to manufacture products from EU, Health Canada and Japanese Health Authority.

Marksans Pharma acquires Teva’s manufacturing site in Goa

Drug firm Marksans Pharma on Tuesday said it has inked a pact with Tevapharm India to acquire its Goa-based bulk pharmaceutical formulations business

Marksans Pharma to acquire Tevapharm’s bulk formulations business

Marksans Pharma said that it has entered into a business transfer agreement with Tevapharm India to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations as a going concern on a slump sale basis.

Marksans Pharma to acquire bulk pharmaceutical formulations facility from Tevapharm

The agency continues to take a consolidated view of Marksans and its subsidiaries while arriving at the ratings.

Ind Ra affirms Marksans Pharma long-term issuer rating at ‘A/Positive’

Marksans Pharma Limited is an India-based pharmaceutical company. The Company operates through the manufacture of pharmaceutical formulation segment. The Company is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. It marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The Company has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.

Marksans Pharma Ltd

Marksans Pharma Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Marksans Pharma Looks Attractive

Q2 results this week: Aarti Industries, Abbott India and more

News Video

Suzlon Energy And Marksans Pharma Stocks Buzzing In Trade | Business Lunch | CNBC-TV18

Capacity addition from Tevapharm sends Marksans Pharma up 6%

Marksans Pharma spurts on buying Tevapharm’s bulk formulations biz

Stocks that will see action on October 12

Marksans Pharma rallies ~12% as company to acquire Tevapharm’s Goa facility

Marksans Pharma Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Marksans Pharma Looks Attractive

Q2 results this week: Aarti Industries, Abbott India and more

News Video

Suzlon Energy And Marksans Pharma Stocks Buzzing In Trade | Business Lunch | CNBC-TV18

Capacity addition from Tevapharm sends Marksans Pharma up 6%

Marksans Pharma spurts on buying Tevapharm’s bulk formulations biz

Stocks that will see action on October 12

Marksans Pharma rallies ~12% as company to acquire Tevapharm’s Goa facility

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock